Palantir stock jumps +12% on report of new FDA contract
Dec. 07, 2020 11:14 AM ETPalantir Technologies Inc. (PLTR)PLTRBy: Kim Khan, SA News Editor166 Comments
- Palantir Technologies (PLTR, +12%) is rallying in morning trading after it reportedly inks a 3-year contract with the FDA.
- The contract, to power drug review and inspections, is worth $44.4M, Bloomberg says.
- Newly-public Palantir shares have been easing after a strong November, down more than 7% since a high on Nov. 25 including today's gain.
- Seeking Alpha authors lean slightly bullish on the stock, with 11 bullish or very bullish, eight neutral and two bearish.